{"entity":{"id":"nct06163430","kind":"trial","name":"A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)","aka":["CARDINAL"],"tldr":"A phase 1/2 trial of TERN-701 in chronic myeloid leukaemia, run by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), now recruiting.","summary":"A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) is a phase 1/2 interventional study registered as NCT06163430 by Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), with 180 participants planned, started 2024-03-26 and due to reach its primary completion in 2029-11-30. Interventions recorded: TERN-701.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06163430","url":"https://clinicaltrials.gov/study/NCT06163430"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06163430","phase":"1/2","setting":"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia","sponsor":"Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","participation":[{"nct":"NCT06163430","source":"https://clinicaltrials.gov/study/NCT06163430","fetchedAt":"2026-10-07T16:54:16.815Z","studySha256":"93ca69b4b2330ec47b147552167b37abcd888d97ac67a5c93bb5c5aed0d02be7","overallStatus":"RECRUITING","lastUpdatePosted":"2026-01-12","leadSponsor":"Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":180,"enrolmentType":"ESTIMATED","siteCount":54,"recruitingSiteCount":48,"countries":["Australia","France","Germany","Italy","New Zealand","South Korea","Spain","United Kingdom","United States"]}],"started":"2024-03-26","startedType":"actual","enrolled":180,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06163430/","neighbours":{"cancer":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"},{"id":"cml-chronic-phase","kind":"cancer","name":"Chronic myeloid leukaemia, chronic phase","route":"/cancers/cml-chronic-phase/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}